N-
acetyl-seryl-aspartyl-lysyl-proline (
AcSDKP) is a natural inhibitor of pluripotent hematopoietic stem cell proliferation and is normally found in human plasma. Because
AcSDKP is hydrolyzed by the N-terminal active site of
angiotensin converting enzyme and partially eliminated in urine, its plasma level is a result of a complex balance between its production, hydrolysis by ACE, and renal elimination. In this study, we attempted to establish an
enzyme immunoassay (EIA) for quantifying
AcSDKP-like immunoreactive substance (IS), which is applicable for monitoring plasma
AcSDKP levels in healthy subjects and patients with
chronic renal failure. Using β-D-
galactosidase-labeled Gly-γAbu-SDKP as a
marker antigen, an anti-rabbit
IgG-coated immunoplate as a bound/free separator and 4-methylumbelliferyl-β-D-galactopyranoside as a
fluorogenic substrate, a highly sensitive and specific EIA was developed for the quantification of
AcSDKP-IS in human plasma. The lower limit of quantification was 0.32 fmol/well, and the sharp inhibition competitive EIA calibration curve obtained was linear between 8.0 and 513 fmol/ml. This EIA was so sensitive that only 10 µl plasma sample was required for a single assay. The coefficients of variation (reproducibility) for human plasma concentrations of 0.2 and 2.1 pmol/ml were 7.2 and 7.7%, respectively, for inter-assay and 13.3 and 7.8% for intra-assay comparisons. Plasma
AcSDKP-IS level was significantly higher in patients with
chronic renal failure (0.92 ± 0.39 pmol/ml) compared with healthy subjects (0.29 ± 0.07 pmol/ml). These results suggest that our EIA may be useful to evaluate plasma
AcSDKP level as a
biomarker in various patients.